Remdesivir and its antiviral activity against COVID-19: A systematic review
Open Access
- 7 August 2020
- journal article
- review article
- Published by Elsevier BV in Clinical Epidemiology and Global Health
- Vol. 9, 123-127
- https://doi.org/10.1016/j.cegh.2020.07.011
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research, 2019
- Remdesivir (GS-5734) protects African green monkeys from Nipah virus challengeScience Translational Medicine, 2019
- Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by RemdesivirViruses, 2019
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studiesVeterinary Microbiology, 2018
- Recombinant RNA-Dependent RNA Polymerase Complex of Ebola VirusScientific Reports, 2018
- In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virusScientific Reports, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and ParamyxovirusesScientific Reports, 2017
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016